Lawrence (Lance) Prince, MD, PhD, is the Division Chief for Neonatal and Developmental Medicine at Stanford. Dr. Prince‚Äôs research interests include the molecular and cellular mechanisms controlling lung development and the maturation of the fetal and neonatal immune systems. He has a particular clinical interest in managing and treating neonatal lung diseases, especially bronchopulmonary dysplasia (BPD) in babies born extremely preterm. Dr. Prince‚Äôs research team focuses primarily on the development of innate immunity during fetal life as it impacts health and disease in preterm infants. The laboratory is investigating how microbes including Group B streptococcus exploit the unique features of neonatal macrophages to avoid immune detection and cause disease, as well as leading a number of clinical and translational investigations.
Neonatal Molecular Precision Medicine and Disease Resilience
While the complications of extreme prematurity can be devastating, many patient have excellent outcomes. In studying the molecular basis for the chronic lung disease bronchopulmonary dysplasia, we identified programs of gene expression correlating with disease protection or resilience. We hope that future genomic studies will help identify therapies that will help achieve normal human development.
Stephen Kingsmore, Rady Children‚Äôs Institute for Genomic Medicine
Kate Kernan, UPMC
The rapid development of genomic sequencing technologies has decreased the cost of genetic analysis to the extent that it seems plausible that genome-scale sequencing could have widespread availability in pediatric care. Genomic sequencing provides a powerful diagnostic modality for patients who manifest symptoms of monogenic disease and an opportunity to detect health conditions before their development. However, many technical, clinical, ethical, and societal challenges should be addressed before such technology is widely deployed in pediatric practice.